Back to top
more

KalVista Pharmaceuticals (KALV)

(Delayed Data from NSDQ)

$11.41 USD

11.41
422,379

+0.16 (1.42%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $11.39 -0.02 (-0.18%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Are Options Traders Betting on a Big Move in KalVista Pharmaceuticals (KALV) Stock?

by Zacks Equity Research

Investors need to pay close attention to KalVista Pharmaceuticals (KALV) stock based on the movements in the options market lately.

KalVista Pharmaceuticals (KALV) Catches Eye: Stock Jumps 7.4%

by Zacks Equity Research

KalVista Pharmaceuticals (KALV) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Corcept (CORT) Q4 Earnings In-Line with Estimates, Up Y/Y

by Zacks Equity Research

Corcept Therapeutics (CORT) reports in-line earnings in the fourth quarter of 2020.

Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues In Line

by Zacks Equity Research

Pacira (PCRX) beats earnings estimates in the fourth quarter of 2019. Revenues are in line with estimates.

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

by Zacks Equity Research

The Zacks Analyst Blog Highlights: ResMed, Ensign, DaVita, KalVista Pharmaceuticals and MEI Pharma

Zoetis' (ZTS) Earnings and Revenues Beat Estimates in Q4

by Zacks Equity Research

Zoetis (ZTS) beats on both earnings and sales in the fourth quarter of 2019.

New Covid-19 Cases Increase, 5 Defensive Stocks to Buy

by Zacks Equity Research

Here are five defensive stocks that can shield your portfolio as Covid-19 continues to spread, instilling volatility in the stock market.

FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA

by Zacks Equity Research

The FDA accepts FibroGen's (FGEN) NDA for roxadustat for the treatment of anemia of chronic kidney disease in both non-dialysis-dependent and dialysis-dependent patients.

The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Calavo Growers, Darling Ingredients, The Simply Good Foods Company, KalVista Pharmaceuticals and CareDx

5 Defensive Stocks to Counter Coronavirus Scare

by Zacks Equity Research

Here are five defensive stocks that can shield your portfolio from China's coronavirus that intimidates to weigh on the stock market.

BioLineRx Concludes Recruitment in Pancreatic Cancer Study

by Zacks Equity Research

BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.

Will KalVista Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals.

Kinjel Shah headshot

Prospects Appear Bright for Small Drug Industry in 2020

by Kinjel Shah

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity keep small drugmakers afloat in a competitive market.

Will KalVista Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in KalVista.

KalVista Pharmaceuticals, Inc. (KALV) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in KalVista Pharmaceuticals, Inc. (KALV).

KalVista Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

KalVista Pharmaceuticals Enters Oversold Territory

by Zacks Equity Research

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

KalVista Group Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

KalVista Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

KalVista Pharmaceuticals Enters Oversold Territory

by Zacks Equity Research

KalVista Pharmaceuticals has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Moving Average Crossover Alert: KalVista Pharmaceuticals

by Zacks Equity Research

KalVista Pharmaceuticals, Inc. (KALV) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Rigel Initiates Enrollment in Pivotal Blood Disorder Study

by Zacks Equity Research

Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.

KalVista Pharmaceuticals (KALV) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

KalVista Pharmaceuticals (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Kinjel Shah headshot

Small Drug Stocks Outlook: Near-Term Prospects Encouraging

by Kinjel Shah

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaboration and M&A activity keep small drugmakers afloat in a competitive market.

Kinjel Shah headshot

Small Drugmakers Outperforming the Bigshots: 7 Stocks to Buy

by Kinjel Shah

Smaller drugmakers are having a relatively better 2019 than their larger counterparts. Here are seven stocks to buy.

What Makes KalVista Pharmaceuticals (KALV) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does KalVista Pharmaceuticals (KALV) have what it takes to be a top stock pick for momentum investors? Let's find out.